P32-specific CAR T cells with dual antitumor and antiangiogenic therapeutic potential in gliomas.

ABSTRACT: Glioblastoma is considered one of the most aggressive malignancies in adult and pediatric patients. Despite decades of research no curative treatment is available and it thus remains associated with a very dismal prognosis. Although recent pre-clinical and clinical studies have demonstrated the feasibility of chimeric antigen receptors (CAR) T cell immunotherapeutic approach in glioblastoma, tumor heterogeneity and antigen loss remain among one of the most important challenges to be addressed. In this study, we identify p32/gC1qR/HABP/C1qBP to be specifically expressed on the surface of glioma cells, making it a suitable tumor associated antigen for redirected CAR T cell therapy. We generate p32 CAR T cells and find them to recognize and specifically eliminate p32 expressing glioma cells a

SUBMITTER: Rousso-Noori L 

PROVIDER: S-EPMC8203650 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature